Interleukin 1b (IL-1b) is an important inflammatory mediator of type 2 diabetes. Here we show that oligomers of islet amyloid polypeptide (IAPP), a protein that forms amyloid deposits in the pancreas during type 2 diabetes, triggered the NLRP3 inflammasome and generated mature IL-1b. One therapy for type 2 diabetes, glyburide, suppressed IAPP-mediated IL-1b production in vitro. Processing of IL-1b initiated by IAPP first required priming, a process that involved glucose metabolism and was facilitated by minimally oxidized low-density lipoprotein. Finally, mice transgenic for human IAPP had more IL-1b in pancreatic islets, which localized together with amyloid and macrophages. Our findings identify previously unknown mechanisms in the pathogenesis of type 2 diabetes and treatment of pathology caused by IAPP.
Type 2 diabetes is characterized by insulin resistance and islet betacell dysfunction, with the progressive loss of insulin release being responsible for ever-increasing glucose concentrations in the absence of treatment 1 . Obesity is frequently the basis for insulin resistance in type 2 diabetes and is associated with higher concentrations of oxidized low-density lipoprotein (LDL) 2 , free fatty acids and proinflammatory cytokines 1 . One cytokine in particular, interleukin 1β (IL-1β), has a profound effect on the function of pancreatic beta cells, inducing them to undergo apoptosis 3 . Abundant literature describes the involvement of IL-1β in type 1 diabetes; however, IL-1β is also a risk factor for type 2 diabetes 4 , and results of a clinical trial of IL-1 blockade in type 2 diabetes have been very encouraging 5 . These data suggest a role for IL-1β in the pathogenesis of type 2 diabetes; however, the events that lead to higher concentrations of active, secreted IL-1β in this disease remain unclear.
Many publications have elucidated mechanisms by which biologically active IL-1β is made in the cell. This usually involves activation of a protein complex called the inflammasome, which is formed by a nucleating sensor protein (typically a member of the NLR (Nod-like receptor) family) that oligomerizes the adaptor protein ASC (apoptosis-associated speck-like protein containing a caspase-recruitment domain) to dimerize and activate caspase-1 and thus cleave the precursor form of IL-1β (pro-IL-1β) into the processed, secreted form. Before this can happen, certain cell types require priming to induce suitable amounts of pro-IL-1β and NLR proteins; this is sometimes referred to as 'signal 1' . The 'signal 2' factors that can activate the nucleating receptor of the complex are still being determined. These include microbial DNA, RNA, cell-wall components and toxins. As for inflammatory diseases such as gout and fibrosing disorders, endogenous factors and environmental contaminants have also been identified, such as uric acid crystals 6 and asbestos or silica, respectively 7 . Most of these molecules activate the inflammasome complex nucleated by NLRP3 (also known as NALP3 or cryopyrin); however, there is no structural similarity to indicate that they would bind to it directly. Instead, NLRP3 is probably a sensor of some homeostatic intracellular process that, if perturbed, will activate the inflammasome. Certainly many of the NLRP3-activating agents seem to perturb the lysosomal vacuole, some because of their size, through a process that has been called 'frustrated phagocytosis' , and others that are not degraded normally once phagocytosed 8 . This prompted us to ask if there might also be an endogenous factor in type 2 diabetes that could activate the NLRP3 inflammasome in this way.
A hallmark feature of type 2 diabetes is the deposition of amyloid in the pancreas of most patients, with this morphological change being A r t i c l e s associated with the loss of insulin-producing beta cells 9 . The unique polypeptide constituent of amyloid found in pancreatic islets is islet amyloid polypeptide (IAPP; also known as amylin) 10, 11 , a 37-amino acid peptide secreted by the beta cell together with insulin. Many lines of evidence link this deposition to disease progression. First there is species specificity, whereby IAPP in certain animals, such as rodents, is unable to form amyloid because of alteration of certain critical residues; however, when a transgene for human IAPP is expressed in mice or rats, amyloid is deposited in pancreatic islets, leading to loss of beta-cell mass [12] [13] [14] . Second, in experiments with nonhuman primates, the concentration of amyloid in the pancreas correlates with the severity of disease and beta-cell function 15 . Third, in humans, the rare S20G polymorphism of IAPP is associated with greater incidence or severity of type 2 diabetes in some populations 16 , and this form of the protein has a greater propensity to form amyloid 17 . IAPP oligomerization might also have a role in the prevention of successful islet transplantation, which is a potential treatment for type 1 diabetes. Amyloid deposition is observed when mouse islets transgenic for human IAPP or human islets are transplanted into mice 18, 19 , and this could also be associated with the failure of islet transplantation in humans 20 .
Initially it was established that IAPP is cytotoxic 21 , and that this could be due to effects at the cell membrane 22 . Mechanistically, this might also involve reactive oxygen species (ROS), because inhibition of ROS prevents IAPP-mediated beta-cell apoptosis in vitro 23 . The process of incorporation of IAPP into amyloid is thought to proceed via the aggregation of prefibrillar oligomers. These soluble oligomers, rather than mature fibrils, could be the cytotoxic component 24 . Amyloid builds up extracellularly, but phagocytosed IAPP can be detected in the lysosomal compartment of human pancreatic macrophages in vivo, where because of its amyloid structure it is not degraded normally 25, 26 . There are also reports showing induction of IL-1β by IAPP 27, 28 ; however, these studies were done before the identification of the inflammasome and did not examine islets or primary macrophages and dendritic cells (DCs), the last two of which could be the main source of pathogenic IL-1β in the pancreas. That observation prompted us to evaluate the potential for IAPP to activate the NLRP3 inflammasome through the mechanism of phagosomal destabilization 8 . Here we show that amyloidogenic human IAPP, but not the nonamyloidogenic rat form of IAPP, triggered inflammasome activation and IL-1β production in lipopolysaccharide (LPS)-primed macrophages or DCs and that this was dependent on NLRP3. Those findings then allowed us to investigate the effect of glyburide, a common treatment for type 2 diabetes, which is known to inhibit the inflammasome 29 . We also found that minimally oxidized LDL (minimally modified LDL (mmLDL)) primed IL-1β processing and that this priming (signal 1) was dependent on glucose metabolism. Finally, we used a mouse model in which the gene encoding human IAPP is expressed in islet beta cells and found higher IL-1β expression that broadly localized together with amyloid and also with macrophages. Our results therefore provide a possible mechanism for IL-1β activation in type 2 diabetes.
RESULTS
IAPP activates the inflammasome to produce mature IL-1b Bone marrow-derived DCs (BMDCs) and bone marrow-derived macrophages (BMDMs) are commonly used to investigate the inflammasome because of their high expression of pro-IL-1β after LPS priming. We compared the ability of IAPP to stimulate production of mature IL-1β from LPS-primed BMDCs with the ability of known inflammasome-activating agents, such as particulate adjuvants, to do so 30 . Overnight stimulation with human IAPP generated IL-1β amounts similar to those generated by stimulation with the adjuvants, but rat IAPP, which is unable to form amyloid, did not stimulate IL-1β release (Fig. 1a) . Human IAPP also stimulated the release of IL-1α, which, like IL-1β, has been shown to rely on caspase-1 activity 31 but could also represent paracrine induction of IL-1α by IL-1β. IL-1α was not less abundant in cell lysates (Supplementary Fig. 1a) , which suggests that full-length IL-1α is not released by cell lysis. The production of tumor necrosis factor (TNF) and IL-6 was undetectable without A r t i c l e s LPS stimulation (Fig. 1a) , which indicated that the IAPP preparations were not contaminated with LPS. The concentrations of TNF and IL-6 were not altered by the presence of IAPP, which indicated that there was a specific effect on IL-1β production, not a general increase in the production of proinflammatory cytokines, and that there was no obvious cell death before these cytokines were produced. Immunoblot analysis confirmed that the IL-1β detected was the cleaved 17.5-kilodalton (kDa) fragment. There was more cleaved IL-1β in the presence of IAPP and the inflammasome-activating agents uric acid crystals (MSU) and ATP than in their absence (Fig. 1b) . We measured lactate dehydrogenase in the supernatants along with IL-1α, and also IL-1β in cell lysates; this confirmed that there was no obvious cytotoxicity under these conditions ( Supplementary Fig. 1a-d) . Both DCs and macrophages are found in pancreatic islets, and these cells have been observed to phagocytose IAPP in type 2 diabetes 26 . Like BMDCs, BMDMs also produced a significant amount of IL-1β in response to IAPP. In contrast, the production of IL-1β by purified mouse pancreatic islets ex vivo and the rat pancreatic beta-cell line Rin-5F was very low, even when these cells were cultured under hyperglycemic conditions (Fig. 1c) . These results show that amyloidogenic human IAPP can trigger IL-1β processing in BMDMs and BMDCs.
IAPP activates caspase-1 and the formation of ASC specks Caspase-1 is the protease activated in the inflammasome complex to cleave IL-1β; we measured active caspase-1 with a cell-permeable probe that covalently binds to activated caspase-1 and fluoresces (FAM-YVAD-fmk). Flow cytometry indicated that the percentage of BMDCs containing active caspase-1 was much higher after stimulation for 1 h with IAPP (Fig. 1d) . The mechanism by which caspase-1 is activated to produce mature IL-1β requires ASC and its ability to form the multimeric inflammasome complex. Normally ASC is evenly distributed throughout the cell cytoplasm, but when the inflammasome complex becomes activated, ASC aggregates to a single focus in the cell, known as a 'speck' . We used immortalized BMDMs that stably express a fluorescent ASC protein to measure speck formation. LPS-treated cells activated with IAPP induced the formation of an intense, single fluorescent speck in the cell indicative of inflammasome activation ( Fig. 1e and Supplementary  Fig. 1e ). In addition to activating IL-1β processing, IAPP therefore also activates caspase-1 and the ASC inflammasome complex.
IAPP oligomers activate the NLRP3 inflammasome
Having shown that an inflammasome complex containing caspase-1 and ASC was activated by IAPP to cleave IL-1β, we next determined which NLR protein nucleates this inflammasome complex. We elected to study NLRP3, which is required for inflammasome activation by particles, rather than IPAF, NLRP1, Nod1 or Nod2, which are not. We found that in NLRP3-deficient BMDCs, the production of mature IL-1β in response to IAPP was completely abrogated (Fig. 2a) . These cells still produced TNF and IL-6, which attested to the specificity of the NLRP3 deletion, and IL-1β mRNA expression was not lower (Supplementary Fig. 1f ). To determine whether oligomers or IAPP fibrils activate the NLRP3 inflammasome, we used the organic solvent HFIP to dissolve amyloid fibrils. We then removed HFIP with nitrogen gas, reconstituted the IAPP in H 2 O or phosphate-buffered A r t i c l e s saline (PBS) and incubated samples at 25 °C. We used thioflavin T fluorescence to indicate fibrillar content. IAPP fibrils formed over 24 h, and this was faster in samples reconstituted in PBS than in those reconstituted in H 2 O (Fig. 2b, left) . This increase in fibrillar content coincided with a decrease in IL-1β production by BMDCs (Fig. 2b, right) . To further elucidate the active species, we subjected preparations of IAPP to size fractionation, generating samples with predominantly fibrillar (>100-kDa) species or oligomeric (<100-kDa) species. We found that the IL-1β-activating potential was retained mainly in the oligomeric fraction of less than 100 kDa from freshly reconstituted IAPP (Fig. 2c) . Collectively these data suggest that the NLRP3-activating constituent is a soluble oligomer of IAPP rather than a highly fibrillar species of high molecular weight.
Inflammasome activation involves the phagolysosome
To confirm the role of caspase-1 and support the use of inhibitors to investigate mechanisms of inflammasome activation, we added a caspase-1 inhibitor to BMDCs before IAPP activation. Caspase-1 inhibition decreased IL-1β production in a dose-dependent manner (Fig. 2d) . IAPP is thought to signal through a complex of receptor activity-modifying proteins with the calcitonin receptor, and the biological effects of IAPP can be blocked at this point with a specific peptide inhibitor (AC187) 32 . To determine if recognition of IAPP by the receptor complex is required for inflammasome activation, we used a 'titration' of up to 40 μM AC187 (a fourfold molar excess); however, this had no effect on IL-1β (Fig. 2d) . Alternatively, IAPP could be phagocytosed by BMDCs and thereby activate the inflammasome in a manner similar to that of other species of amyloid 33 . Inhibition of IL-1β production after the addition of cytochalasin D confirmed that inflammasome activation was dependent on phagocytosis (Fig. 2d) . Furthermore, inhibition of the vacuolar H + ATPase by bafilomycin A restricted the effect of IAPP on IL-1β secretion (Fig. 2d) . Together these results suggest that phagolysosomal processes downstream of acidification are altered to trigger NLRP3 activation.
Activation of the inflammasome by IAPP prevented by glyburide
Two mechanisms have been proposed to account for perturbations in phagocytic processes that activate the inflammasome. Cathepsin B has been linked to this process for amyloid-β 33 , whereas IAPP 23 and MSU 6 have been found to induce ROS. We used the ROS inhibitor APDC and the cathepsin B inhibitor CA-074 Me to confirm the role of ROS and cathepsin B in IAPP activation of the inflammasome (Fig. 2e) . Glyburide is a second-generation sulfonylurea, an agonist of the potassium channel composed of SUR1 and KIR6.2 that signals for more insulin secretion. Additionally, this small-molecule agonist inhibits the inflammasome and IL-1β production, but this is independent of its interaction with the SUR1-KIR6.2 complex 29, 34 . We found that activation of the NLRP3 inflammasome by IAPP was also inhibited by glyburide (Fig. 2e) .
TXNIP is not involved in IAPP activation of IL-1b
The thioredoxin-interacting protein TXNIP has been identified as a redox-sensitive ligand of NLRP3 (ref. 35) . That study suggested that a higher concentration of glucose alone induces pancreatic beta-cell 
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TXNIP to activate the inflammasome and that glyburide prevents this. However, it also showed that TXNIP expression in macrophages is constitutively high, so it is unlikely that this would be the mechanism of inflammasome inhibition by glyburide in macrophages. Nevertheless, we formally examined TXNIP mRNA both before and after LPS priming in BMDMs and found no difference due to glyburide in either setting (Supplementary Fig. 2a) . Furthermore, LPS resulted in lower expression of TXNIP, which challenged the idea that this protein is the instigator of NLRP3 activation in BMDMs. We then tested TXNIP-deficient macrophages to determine if this NLRP3 ligand was required for IL-1β production in response to IAPP (Supplementary Fig. 2b ). We found no difference in IL-1β secretion in response to IAPP or indeed other inflammasome activators, such as MSU or ATP, in BMDMs ex vivo. In addition, we directly compared IL-1β secretion and caspase-1 activation by BMDMs from mice lacking TXNIP or NLRP3 and found that these parameters were lower only in Nlrp3 −/− mice ( Supplementary Fig. 2c-f) . Therefore, our studies did not identify a role for TXNIP in regulating the effect of glyburide on the inflammasome or on IL-1β production by the inflammasome, in BMDMs.
Glucose metabolism required for inflammasome priming Higher concentrations of d-glucose, similar to those encountered in type 2 diabetes, can induce pro-IL-1β 36, 37 , although this is debated 38 . Growing BMDMs in various concentrations of glucose influenced cell proliferation, to which BMDCs were more resistant. We therefore tested BMDCs for up to 24 h in hyperglycemic conditions (25 mM d-glucose) either before or after priming with LPS. We saw no substantial difference in IL-1β production after IAPP stimulation (Fig. 3a) .
We also tested two d-glucose analogs: one that is not metabolized by the cell and provides an osmotic environment similar to that provided by d-glucose (l-glucose), and another that actually inhibits the processing of d-glucose and subsequent metabolic processes in the cell (2-deoxy-d-glucose (2DG)). We found that l-glucose had no effect (Fig. 3a) ; however, low concentrations of 2DG prevented IL-1β release due to IAPP in a dose-dependent manner (Fig. 3b) . We also found that 2DG had no effect when added after the addition of LPS and instead had an effect only before the addition of IAPP (Fig. 3b) , and that 2DG prevented the induction of IL-1β mRNA during LPS priming of the inflammasome (Fig. 3c) . There was also slightly less production of IL-6 at the highest concentration of 2DG (Fig. 3b) ; however, the production of TNF and the viability of cells in general were not perturbed ( Fig. 3b and Supplementary Fig. 3a) . Sufficient glucose metabolism is therefore required in vitro during priming (signal 1) of the inflammasome.
IAPP-activated inflammasomes primed by mmLDL
Our studies to this point showed that glucose metabolism was required for LPS to prime the inflammasome, after which IAPP activated NLRP3, caspase-1 and ASC, leading to IL-1β processing. The question then arose as to an endogenous priming agent of the NLRP3 inflammasome rather than exogenous LPS. It has been reported that mmLDL can engage Toll-like receptor 4 (TLR4) in a manner similar to LPS, whereas extensively oxidized LDL does not 39 . Specifically, people with type 2 diabetes can have higher concentrations of mmLDL 40, 41 , and mmLDL can cause apoptosis and a loss of insulin secretion by islets in culture 42 . We therefore tested preparations of LDL that had been oxidized to various extents. Although the production of IL-1β after activation of the inflammasome by IAPP was low when it was first primed with mmLDL, that was greater than after priming with more extensively oxidized species of LDL or LDL that was not oxidized (Fig. 4a) . The recognition of mmLDL depended on TLR4, because C3H/HeJ mice, which have a nonfunctional TLR4, were unable to prime the inflammasome via LPS or mmLDL. We found that mmLDL also resulted in the dose-dependent production of TNF and IL-6 (Fig. 4b) . We did not detect LPS in mmLDL preparations; however, the LPS inhibitor polymyxin B inactivated mmLDL (Supplementary Fig. 3b ). Although trace amounts of LPS might be specifically presented to TLR4 by mmLDL, it is also possible that polymyxin B neutralizes mmLDL in the same way as LPS. There are thought to be two prerequisites for inflammasome priming, the induction of pro-IL-1β and NLRP3 (ref . 43) ; however, we observed that mmLDL induced only IL-1β mRNA, in a time-dependent manner (Fig. 4c) . This lack of NLRP3 upregulation might help explain the small amount of IL-1β activation relative to A r t i c l e s LPS priming. Nevertheless, these data suggest that mmLDL can promote IL-1β by providing signal 1 (priming) to the inflammasome, which may be particularly relevant in type 2 diabetes.
IAPP induces IL-1b in vivo
As mouse IAPP is not amyloidogenic, mice transgenic for the expression of human IAPP have been generated and characterized extensively as a rodent model of islet amyloid formation 44 . In particular, when these mice are fed a high-fat diet, amyloid deposition in islets of the pancreas occurs and is associated with impaired function of insulin-producing cells 45 . We fed wild-type (control) mice and IAPPtransgenic mice a high-fat diet for 1 year (the length of time required in this model) and then determined by immunofluoresence whether insulin and IL-1β were present in pancreatic islets (Fig. 5a) . Although it was variable, IAPP-transgenic mice had regions in the islet that did not stain for insulin; instead, these regions showed evidence of IL-1β immunoreactivity. However, the IL-1β staining colocalized to regions where amyloid was deposited, as determined by staining with thioflavin S (Fig. 5b) . To identify the cell type in the islet that produces this IL-1β, we stained samples with MoMa2, an antibody that is particularly useful for detecting peripheral tissue macrophages (Fig. 5c) . Most of the macrophages in the islet were positive for IL-1β, but there was still a large area staining for IL-1β outside these cells. When we quantified these results, we observed a significantly smaller area of insulin-producing cells (Fig. 5d) , with concurrently more amyloid (Fig. 5e) and a larger area of IL-1β expression (Fig. 5f ) in the pancreatic islets of IAPP-transgenic mice. There was no significant difference in the area of MoMa2 reactivity in the islet (Fig. 5g) . This mouse model indicates that the presence of IAPP amyloid promotes IL-1β in vivo.
DISCUSSION
Our work here has described the mechanism whereby an endogenous molecule deposited in the pancreas during type 2 diabetes can potentiate the processing of IL-1β, a pathogenic cytokine that causes betacell death. We also found release of IL-1α due to IAPP, which could augment sterile inflammation in pancreatic islets. Our observation that IAPP activated the NLRP3 inflammasome is consistent with similar activation by a different amyloidogenic peptide, amyloid-β 33 , and literature showing that the disease-causing species of IAPP might be oligomers 46 . Macrophages and DCs are professional phagocytic cells that take up IAPP in pancreatic islets, and we found that these cell types produced substantial amounts of IL-1β in response to IAPP oligomers. Using various inhibitors, we showed that pertubation of the phagolysosomal pathway seemed to be involved in the activation of NLRP3 by IAPP; however, the role of ROS may be complex. Papers have shown that patients deficient in ROS production still activate the inflammasome to an even greater degree than do healthy controls with normal ROS production 47 . This suggests that the effect of the ROS inhibitor that we used might have been nonspecific, and indeed this is a caveat raised for the use of inhibitors in general. Although the effects of the inhibitors we used probably point toward a common mechanism of inflammasome activation during the phagocytosis of IAPP, their precise target in this pathway remains to be elucidated. We found no evidence that the signaling cascade leading to NLRP3 activation requires TXNIP. In particular for type 2 diabetes, in which TXNIP is known to be a ROS-sensitive molecule linked to disease, we had hypothesized that IAPP-induced changes would use this pathway. Although it is possible that our in vitro experiments did not fully recapitulate the in vivo mechanisms of disease, they have shown that NLRP3 was a critical mediator of IL-1β release, whereas TXNIP was not. Certainly cell-type differences might account for our observation, as TXNIP mRNA was not altered by glyburide in macrophages, whereas others have reported that glyburide might prevent TXNIP induction in beta cells 35 . Because IAPP induced substantial IL-1β production from macrophages and this was inhibited by glyburide, whereas TXNIP mRNA remained unchanged, a separate mechanism for this inhibition must exist and is sure to attract interest in the future. Although we found that glyburide inhibited IAPP-induced IL-1β in vitro at concentrations above 5 μg/ml, it is unlikely that the dose of glyburide now used clinically would reach this concentration. New small molecules that can target this inflammatory pathway in vivo will probably be therapeutic candidates.
The identification of IAPP as a possible trigger for inflammasome activation in type 2 diabetes still leaves open the question of which endogenous factors prime the inflammasome in this disease. A high concentration of glucose alone was not able to replace LPS as the priming agent or influence IL-1β mRNA. We found that mmLDL primed the inflammasome through TLR4; however, extensively oxidized LDL, which does not engage this receptor, did not. This is a potential mechanism by which mmLDL might be associated with type 2 diabetes and other IL-1β-dependent manifestations such as atherosclerosis 48 . Further involvement of LDL in inflammasome activation has also been described, in which it facilitates deposition of cholesterol crystals in the vessel wall 48 . Although the role of mmLDL in type 2 diabetes has not been characterized extensively, free fatty acids are commonly thought of as being potentially pathogenic in type 2 diabetes. On the basis of the literature, we would expect that free fatty acids could also prime the inflammasome by interaction with TLRs 49 .
Although increasing the glucose concentration had no effect on IL-1β activation in our in vitro assays, we found that glucose metabolism was required for the induction of pro-IL-1β expression by LPS in macrophages. To inhibit glucose metabolism, we used 2DG, which has also been found to decrease IL-1β in vivo, as in atherosclerosis-prone, insulin-resistant rats 50 . The in vivo effects of IL-1β in terms of fever and inflammation are highly energy-dependent processes. Thus, it would be appropriate for cells to prevent IL-1β production unless there is sufficient glucose that can be metabolized to mediate these biological responses. We observed slightly less IL-6 production; however, it is likely that the factors that control IL-1β synthesis that are inhibited by 2DG are also shared in some part by other proinflammatory cytokines. Because we found glucose metabolism to be a limiting step in inflammasome priming, this could be a physiologically relevant mechanism in the pathogenesis of type 2 diabetes by which persistent hyperglycemia might abolish any such limits. Indeed, the beta-cell loss in IAPP-transgenic mice fed a high-fat diet is much greater when they develop amyloid deposition 45 , and we have now reported that this was associated with a significant increase in IL-1β immunostaining. The IL-1β observed in islets of IAPP-transgenic mice localized together with macrophages and also with amyloid. We found no evidence of IL-1β production by beta cells, and if they do produce IL-1β, it is probably a small amount or a rare event. Although IL-1β staining in macrophages might represent intracellular pro-IL-1β, staining outside these cells that is coincident with amyloid could represent the secreted, processed form, as there are few live cells in these regions. Our analysis is somewhat limited in this context, as the antibody we used to detect IL-1β would recognize both the processed and pro-IL-1β species.
Our data were unambiguous about the ability of IAPP to activate the NLRP3 inflammasome and generate processed IL-1β. This might be a key mechanism for IL-1β production in type 2 diabetes. It could be that amyloid deposition in the pancreas happens only later in the A r t i c l e s disease process, and some have argued that this would be a result, not as a cause, of disease. However, it is also possible that even if this buildup is secondary to the initiation of disease, it nevertheless aids the progressive loss of beta-cell function that is a key component of type 2 diabetes. Future studies of patients should identify whether targeting IL-1 has the most benefit only later in disease progression or for those with more severe disease pathology. It is also becoming apparent that IAPP could contribute to the death of transplanted islets being used as therapy in type 1 diabetes [18] [19] [20] . The current Edmonton protocol of immunosuppression used during this transplant procedure could conceivably be improved with anti-inflammatory therapy targeting IL-1β activated by IAPP. In conclusion, our findings have highlighted previously unknown roles for well-known entities in the pathogenesis and treatment of diabetes, and we hope they will spur new research targeted at the mechanisms of this debilitating, chronic disease.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/natureimmunology/.
